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successfully treated and not successfully treated with prescrip-
tion medication alone. Resource use included type and number
of physician visits, diagnostic tests, and type and number of OAB
complications, as well as monthly out-of-pocket expenses asso-
ciated with OAB, such as over the counter medications, co-pay-
ments for prescription medications, incontinence pads, and
laundry and dry cleaning. Statistical signiﬁcance was evaluated
at the a = 0.05 level. RESULTS: In total, 196 adults receiving
drug therapy for their OAB (mean age 63.4 years, 76% female)
responded to the survey, of whom 121 (62%) perceived them-
selves to be successfully treated. In general, respondents who
considered their OAB condition successfully treated tended to
consume signiﬁcantly fewer resources than respondents who
considered their OAB unsuccessfully treated, including: visits to
a primary care physician (0.9 vs 1.4, p < 0.01); urine tests (0.2
vs 0.5, p = 0.05); and pads used during the day (0.9 vs 1.9, p <
0.01); and experienced fewer urinary tract infections (0.3 vs 0.9,
p < 0.02). Median monthly out-of-pocket expenses for OAB
were $18 for successfully treated versus $30 for unsuccessfully
treated respondents (p < 0.05). CONCLUSIONS: Patients who
consider themselves successfully treated with OAB medications
consume fewer resources and incur fewer out-of-pocket
expenses. OAB drug therapies that increase patient perception of
treatment success could potentially lead to lower healthcare
resource consumption.
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OBJECTIVE: Reducing protein intake of patients with chronic
renal disease (CRD) signiﬁcantly reduces the number of patients
entering end-stage renal disease (ESRD). We conducted an eco-
nomic evaluation of dietary protein restriction on the progres-
sion of CRD. METHODS: We conducted a Cost-Beneﬁt Analysis
in the perspective of the Italian National Health Service (NHS)
based on data from Modiﬁcation in Diet in Renal Disease
(MDRD) Study. In the MDRD, patients with a glomerular ﬁl-
tration rates (GFR) of 25–55ml/min/1.73m2 were randomly
assigned to usual protein (1.3g/Kg/die) or low protein 
(0.58g/Kg/die) diet groups. It is expected that a patient would
receive a protein-restricted diet when his/her GFR falls under 
25ml/min/1.73m2 and to start dialysis when his/her GFR is 
5ml/min/1.73m2. We quantiﬁed cost of diet with aprotein
product (2000Kcal/die, 40gr/die of protein) and the assistance
of a nutritionist (once every two months) and cost of dialysis
using NHS tariffs. Data were applied to a 7 years time horizon.
We conducted a one-way sensitivity analysis varying costs and
beneﬁts by ± 10% and applied a 3% rate of discount. RESULTS:
Applying the mean decline of GFR obtained by the MDRD study
we estimated patients receiving a low protein intake to start dial-
ysis in 7 years. Patients with a usual protein diet would start dial-
ysis in 5 years. We estimated a cost of 6882€ for 7 years low
protein diet with aprotein products. This treatment would delay
by 2 years dialysis initiation with an estimated saving to the NHS
of 43,268€. We obtained a beneﬁt of 36,386€ per patient. These
results were robust in one-way sensitivity analyses. CONCLU-
SION: Using MDRD Study data, a low protein controlled diet,
in nephropatic patients, could delay the degeneration of
nephropathy extending the renal survival. This involves signi-
ﬁcative economic beneﬁts.
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OBJECTIVE: The objective of this project was to analyse the 1-
year direct medical costs of kidney transplantation performed in
Belgium. METHODS: Data from the last 150 patients who
received a kidney transplantation at UCL Cliniques Universi-
taires St Luc (Belgium) and for which a follow-up of 1-year was
available were analysed. All patients were adults at the age of
the transplantation and treated with cyclosporine. Patients ﬁles
were retrospectively analysed. Key parameters, such as: primary
hospitalisation for transplantation; immunosuppressive drug
use; patient survival; graft survival; acute rejection; CMV infec-
tion; other adverse events and serious complications; treatment
of adverse events; treatment of complications; repeat hospital-
ization; and follow-up hospital consultations were recorded.
Total length of stay in the hospital was also recorded. For each
patient, information up to 1-year post renal transplantation (or
until death if death occurred within 1-year of transplantation)
was collected. Costing information was obtained from anony-
mous hospital bills which provided amounts paid by the health
care payer and patient. Three perspectives were considered in
this study, i.e. the health care payer (INAMI/RIZIV), the patient,
and the societal perspectives. RESULTS: For the whole popula-
tion (n = 150), the mean direct medical costs from the societal
perspective, health care payer’s perspective, and patient’s per-
spective amounted to 40,574€, 38,566€ (of which 28,844€ for
hospitalisation only), and 2,008€, respectively. During this one
year period, patients were hospitalised for 29 days on average.
CONCLUSIONS: One year direct medical costs of kidney trans-
plantation are substantial. In Belgium, most of the direct medical
costs are borne by the health care payer, and the main cost driver
are hospital costs.
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OBJECTIVE: This analysis characterizes patients in need of high
EPO doses at still low Hb levels of below 10g/dl (poor EPO
response). Cost-effectiveness of TR in such cohort is assessed.
METHODS: A database (>9000pat.) was stratiﬁed by EPO
dosage and Hb level and analyzed according to several medical
outcome parameters. A cohort of pat with poor EPO response
was compared to patients with an EPO dosis of 2,500–10,600
(mean ± 1 SD) and a mean Hb level of 11.5g/dl. Costs and con-
sequences of EPO therapy and TR were analyzed for the cohort
of pat with poor EPO response. RESULTS: Patients (n = 233)
with poor EPO response (18,730U/week) showed a mean Hb
level of 9.0g/dl and a higher prevalence of cerebrovascular, liver,
and valvular heart disease and fewer days of hospital free sur-
vival time of 223 days compared to 273 days in the compara-
tive arm. The yearly costs of EPO therapy (15,660€) outweigh
the costs of transfusion therapy (5,250€) assuming 50 blood
units per year. CONCLUSION: Given the relatively sick popu-
lation with poor EPO response, the risks associated with TR such
as infections and iron overload is outbalanced. Since mortality
(historical group) and QoL (SF-36) data are available for these
groups, the cost-effectiveness (cost per QALY) will be calculated.
